Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI (GlioCEST)

January 29, 2026 updated by: Centre Paul Strauss

Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions.

Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

For this study the investigators propose to include an additional CEST sequence in standard PET/MRI exam in order to obtain a cartography with biochemical informations from tissues in patients with glioma or brain metastases.

Study Type

Interventional

Enrollment (Estimated)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Strasbourg, France
        • Recruiting
        • France Institut de cancérologie Strasbourg Europe
        • Contact:
        • Principal Investigator:
          • Izzie-Jacques NAMER, MD, PhD
        • Sub-Investigator:
          • Caroline BUND, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to:

  • Preoperative evaluation of a cerebral expansion lesion
  • Evaluation of glioma recurrences
  • Evaluation of brain metastases
  • Evaluation of recurrence of metastases

Exclusion Criteria:

  • Contraindication to the realization of an MRI
  • Minor or patients placed under guardianship or supervision
  • Patients deprived of liberty
  • Patients placed under judicial protection
  • Patients that are not able to express their consent
  • Pregnant and breastfeeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients with glioma or brain metastases
Other: Additional CEST sequences during PET/MRI exam
CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases
Time Frame: through study completion, up to 14 years
Evaluation at the cerebral level on the acquisition images of residual volume in MRI
through study completion, up to 14 years
Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases
Time Frame: through study completion, up to 14 years
Evaluation at the cerebral level on the acquisition images of tumoral metabolic activity in PET
through study completion, up to 14 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Correlate intratissular pH mapping and location of recurrence
Time Frame: through study follow-up, up to 10 years
through study follow-up, up to 10 years
Correlate average pH of the tumor and histopathology
Time Frame: through study follow-up, up to 10 years
through study follow-up, up to 10 years
Correlate average pH of the tumor and Disease-Free Survival (DFS)
Time Frame: through study follow-up, up to 10 years
through study follow-up, up to 10 years
Correlate average pH of the tumor and Overall survival (OS)
Time Frame: through study follow-up, up to 10 years
through study follow-up, up to 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Paul Strauss

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 28, 2022

Primary Completion (Estimated)

December 28, 2036

Study Completion (Estimated)

December 28, 2036

Study Registration Dates

First Submitted

July 12, 2022

First Submitted That Met QC Criteria

July 15, 2022

First Posted (Actual)

July 19, 2022

Study Record Updates

Last Update Posted (Actual)

February 2, 2026

Last Update Submitted That Met QC Criteria

January 29, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-005
  • 2022-A00910-43 (Other Identifier: ID-RCB Number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioma

Clinical Trials on Additional CEST sequences during PET/MRI exam

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe